| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7763615 | JAZZ | Ecteinascidin analogs for use as antitumour agents |
Dec, 2029
(5 years from now) | |
Zepzelca is owned by Jazz.
Zepzelca contains Lurbinectedin.
Zepzelca has a total of 1 drug patent out of which 0 drug patents have expired.
Zepzelca was authorised for market use on 15 June, 2020.
Zepzelca is available in powder;intravenous dosage forms.
Zepzelca can be used as treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy..
Drug patent challenges can be filed against Zepzelca from 15 June, 2024.
The generics of Zepzelca are possible to be released after 13 December, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2025 |
| Orphan Drug Exclusivity(ODE-304) | Jun 15, 2027 |
Drugs and Companies using LURBINECTEDIN ingredient
NCE-1 date: 15 June, 2024
Market Authorisation Date: 15 June, 2020
Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.
Dosage: POWDER;INTRAVENOUS
ZEPZELCA family patents
